Pemoline

Jump to: navigation, search
Pemoline
Pemoline Wiki Str.png
Clinical data
Pregnancy
category
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability50% bound to plasma proteins
MetabolismHepatic
Elimination half-life12 hours
Excretion?
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC9H8N2O2
Molar mass176.172 g/mol

WikiDoc Resources for Pemoline

Articles

Most recent articles on Pemoline

Most cited articles on Pemoline

Review articles on Pemoline

Articles on Pemoline in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pemoline

Images of Pemoline

Photos of Pemoline

Podcasts & MP3s on Pemoline

Videos on Pemoline

Evidence Based Medicine

Cochrane Collaboration on Pemoline

Bandolier on Pemoline

TRIP on Pemoline

Clinical Trials

Ongoing Trials on Pemoline at Clinical Trials.gov

Trial results on Pemoline

Clinical Trials on Pemoline at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pemoline

NICE Guidance on Pemoline

NHS PRODIGY Guidance

FDA on Pemoline

CDC on Pemoline

Books

Books on Pemoline

News

Pemoline in the news

Be alerted to news on Pemoline

News trends on Pemoline

Commentary

Blogs on Pemoline

Definitions

Definitions of Pemoline

Patient Resources / Community

Patient resources on Pemoline

Discussion groups on Pemoline

Patient Handouts on Pemoline

Directions to Hospitals Treating Pemoline

Risk calculators and risk factors for Pemoline

Healthcare Provider Resources

Symptoms of Pemoline

Causes & Risk Factors for Pemoline

Diagnostic studies for Pemoline

Treatment of Pemoline

Continuing Medical Education (CME)

CME Programs on Pemoline

International

Pemoline en Espanol

Pemoline en Francais

Business

Pemoline in the Marketplace

Patents on Pemoline

Experimental / Informatics

List of terms related to Pemoline

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pemoline (sold as Cylert) is a medication used to treat attention-deficit hyperactivity disorder (ADHD) and narcolepsy. Under the Convention on Psychotropic Substances, it is a Schedule IV drug.[1]

Pemoline has some advantages over other stimulants in that it does not reduce the appetite or cause dry mouth.

Hepatotoxicity and discontinuation

In some patients Pemoline is suspected of causing hepatotoxicity, so regular liver tests are performed on those treated with it. Since receiving FDA approval in 1975, it has been linked with 21 cases of liver failure, of which 13 resulted in liver replacement or death. In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline due to pressure from certain public advocacy groups, including Public Citizen. The patient support group "Narcolepsy Network"[2] tried to persuade the FDA not to ban it, on the grounds that some patients find all other treatments ineffective or to have debilitating side effects. The medication was used by an estimated 10,000 Americans afflicted with narcolepsy. A more potent analogue of pemoline, 4-methylaminorex has appeared as a black market drug with abuse potential similar to methamphetamine.

In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.


References

See also

External links

de:Pemolin sv:Pemolin


Linked-in.jpg